Duke Licensee Genetron Health Prices $256M US IPO
Beijing-based Genetron Health on Friday announced pricing of its previously announced initial public offering of 16,000,000 American Depositary Shares, each representing five ordinary company shares at $16.00 per ADS. The gross proceeds from the initial public offering…
Grid Therapeutics Announces Enrollment of 1st Patient in Phase 1 Study
Grid Therapeutics, LLC, a clinical-stage biotechnology company developing a first-in-class, novel, human-derived targeted immunotherapy for solid tumors, today announced that the first patient has been dosed in a Phase 1/2 study of GT103 in patients with…
Replicate Bioscience and Immunomic Therapeutics Form Collaboration to Combat Infectious Diseases and Cancers
ROCKVILLE, Md. & SAN DIEGO–Replicate Bioscience, Inc. (“Replicate”), a privately-held biopharmaceutical company creating novel treatments to prevent drug resistance in cancers, and Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of…
Building A Better Protein Trap
Life scientists love antibodies, not only because these little proteins help protect us all from pathogens, but because antibodies are also a very handy laboratory tool for identifying and marking proteins of interest in their…
Viela Bio Announces U.S. FDA Approval of UPLIZNA™
UPLIZNA™ is the first and only B cell depleter approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 (AQP4) antibody positive Viela Bio (Nasdaq:VIE) today announced that the U.S.…
Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial
June 8, 2020 at 7:00 AM EDT PDF Version -PBCAR269A Targets BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma and is the Company’s Third Investigational Allogeneic CAR T Candidate Advanced to the Clinic – -PBCAR269A…
Chapel Hill startup focusing on precision health, oncology raises additional $1.8M
Xilis, a startup founded by two professors at Duke University focusing on precision health and oncology, has raised an additional $1.85 million in equity, according to a recent securities filing. That brings the total raised to roughly…
PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients
(Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as…
Retinal Texture Could Provide Early Biomarker Of Alzheimer’s Disease
Biomedical engineers at Duke University have devised a new imaging device capable of measuring both the thickness and texture of the various layers of the retina at the back of the eye. The advance could…